Sangamo Biosciences Shares Down 4.5% After Insider Selling (SGMO)
Sangamo Biosciences (NASDAQ:SGMO)’s share price dropped 4.5% on Wednesday after an insider sold shares in the company, Stock Ratings Network reports. The company traded as low as $15.89 and last traded at $15.97, with a volume of 352,706 shares trading hands. The stock had previously closed at $16.73.
Specifically, CEO Edward O. Lanphier II unloaded 25,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $16.41, for a total value of $410,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
The stock has a 50-day moving average of $13.80 and a 200-day moving average of $16.27. The company’s market cap is $1.110 billion.
Sangamo Biosciences (NASDAQ:SGMO) last released its earnings data on Tuesday, May 6th. The company reported ($0.12) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.01. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $6.59 million. During the same quarter last year, the company posted ($0.13) earnings per share. Sangamo Biosciences’s revenue was up 76.1% compared to the same quarter last year. Analysts expect that Sangamo Biosciences will post $-0.29 EPS for the current fiscal year.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.